Authors :
Arefa Khan; Dr. Anamika Singh; Dr. Sapna Malviya; Dr. Anil Kharia
Volume/Issue :
Volume 9 - 2024, Issue 7 - July
Google Scholar :
https://tinyurl.com/2hh8ehba
Scribd :
https://tinyurl.com/5cezpcwj
DOI :
https://doi.org/10.38124/ijisrt/IJISRT24JUL1165
Abstract :
This review provide an overview of the
various documentation of quality management system,
which includes deviations, OOS and CAPA. A detailed
case study of deviations, out-of-Specification and CAPA
generation is beneficial for improving pharmaceutical
capabilities and understanding the documentation
associated with a quality management system. It is
essential for understanding deviations and out-of-spec in
the pharmaceutical industry. The quality of medicines
means that they meet the required specifications. The
quality management system in the pharmaceutical
industry is essential because the drugs or pharmaceutical
products are delivered directly to the customer's body.
Therefore, identity, purity, safety, and the quality of the
products are critical. A Deviation can define as "a
deviation from an approved instruction or established
standard" The deviation process helps identify potential
risks to product quality and patient safety and establish
the root cause. Once the root cause identifies,
appropriate corrective and preventive actions take to
prevent reoccurrence. OOS defines as "A result that is
outside the specifications or acceptance criteria
established by the manufacturer or laboratory" As the
industry moves to newer and more complicated
products, quality control procedures must be in place to
ensure consistent product quality. "CAPA defined by
corrections.
Keywords :
Deviation; Out-of-Specification (OOS); Corrective and Preventive Action (CAPA).
References :
- Choudhhary, A. (2016). Quality assurance: Quality management system. Phrmaguideline.
- Bruun, A.M. (2023). Pharmaceutical: QMS. SimplerQMS.
- Sehrawat, V., & Singh, N. (2017). Quality Management System (QMS). IAETSD Journal for advanced research in applied sciences. (Volume 4, Issue 6). Page no 220-226
- Damini, V., Kumar, S. H., Gangadharappa, V., & Gowrav, M. P. (2020). Handling of Pharmaceutical Deviation: A Detailed Case Stusy. Indian Journal of Pharmaceutical Sciences. Page no 928-944.
- Jadhav, A. A., Gagare, P. S., Kirtane, S., Babar, V. B., Pondkule, A. V., & Nagrale, S.N. (2022). Review on Deviation Management in Pharmaceutical Industry. International Journal of Creative Research Thoughts (IJCRT). (Volume 10, Issue 11). Page no 789-794.
- Alam, A. M. (2020). Deviation Management in Pharmaceutical Industry. ResearchGate.
- Kumar, A. K., & Gupta, N.V. (2015). Handling of Out of Specification Results. International Journal of Pharmaceutical Quality Assurance(IJPQA). Page no 38-44.
- Soni, P., Patel, D., Patel, G., Patel, T., & Mesharam, D. (2022). Importance of quality management system in current scenario: OOS. International Journal of Frontiers in Life Science Research. Page no 016–025.
- Choudhary, A. (2019). Possible Cause of Out of Specification. Pharmaguidelines.
- Rompicherla, N. C., Paul, E., Ganesh, A.,& Narayanan, A. V. (2020). The significance of Quality Metrics in a Pharmaceutical Quality Management System: A Case Based Study. Indian Journal of Pharmaceutical Education and Research. (Volume 54,Issue 3). Page no 798-807
- Mote, N. N. (2021). Reference for Investigation of Out of Specification results in pharmaceutical industry. Austin Pharmacol Pharm. (Volume 6 Issue 1). Page no 1-7.
- Pharmalex confidence beyond compliance. (2018). Out of specification guidance-by MHRA.
- MHRA Inspectorate . Gov.UK (2018). Out of specification guidance.
- Food and Drug Administration Center for Drug Evaluation and Research (CDER). (2022). Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production. USA. Revision 1.
- Savale, S. K. (2018). Out-of-Specification and Out-of-Trend analysis in Pharmaceutical Manufacturing Investigation: A Overview. Resaerchgate. Page no 1-8
- Soni, P., Patel, D., Patel, G., Patel, T., & Mesharam, D. (2022). Importance of quality management system in current scenario: OOS. International Journal of Frontiers in Life Science Research. Page no 016–025.
- Choudhary, A. (2019). Possible Cause of Out of Specification. Pharmaguidelines.
- Mote, N. N. (2021). Reference for Investigation of Out of Specification results in pharmaceutical industry. Austin Pharmacol Pharm. (Volume 6 Issue 1). Page no 1-7.
- Kumar, H. ; Paneesh, C. (2019). Handling Out of Specification During Laboratory Incidence. J. global trends pharma sci, 10(3), 6591-6597.
- ComplianceQUEST complete quality Transformed. (2022).
- Rompicherla, N. C. ; Paul, E. ; Ganesh, A. ; Narayanan, A. V. (2020). The significance of Quality Metrics in a Pharmaceutical Quality Management System – A Case Based Study. Indian Journal of Pharmaceutical Education and Research |Vol 54,Issue 3. Karnataka
- Pharmalex confidence beyond compliance. (2018). Out of specification guidance-by MHRA
- Kumar, V. (2018). MHRA guidelines for out of specification. Volume 2, issue 1.
- Savale, S. K. (2018). Out-of-Specification and Out-of-Trend analysis in Pharmaceutical Manufacturing Investigation: A Overview.
- Raj, A. (2016). A Review on Corrective action and preventive action (CAPA). African Journal of Pharmacy and pharmacology. (Volume 10, Issue 1). Page no 1-6
- Rompicherla, N. C., Paul, E., Ganesh, A.,& Narayanan, A. V. (2020). The significance of Quality Metrics in a Pharmaceutical Quality Management System: A Case Based Study.
- Indian Journal of Pharmaceutical Education and Research. (Volume 54,Issue 3). Page no 798-807
- 21CFR Part 820- Quality system Regulation, subpart-J. 820.100 Corrective and preventive action.
- Chavan, P. A., Bhagwat, A. M., Chaudhari, A. P. (2021). CAPA: An important concept of Quality Assurance in Pharmaceutical Industry. Asian Journal of Research in Chemistry. (Volume 14, Issue 5). Page no 357-359
- Gangadharappa, H.V., Venkatesh, M.P. (2017). Corrective and Preventive Actions: Management and Application in Pharmaceutical Industry. International Journal of Pharmaceutical Sciences Review and Research. (Volume 46, Issue 2). Page no 184-189.
This review provide an overview of the
various documentation of quality management system,
which includes deviations, OOS and CAPA. A detailed
case study of deviations, out-of-Specification and CAPA
generation is beneficial for improving pharmaceutical
capabilities and understanding the documentation
associated with a quality management system. It is
essential for understanding deviations and out-of-spec in
the pharmaceutical industry. The quality of medicines
means that they meet the required specifications. The
quality management system in the pharmaceutical
industry is essential because the drugs or pharmaceutical
products are delivered directly to the customer's body.
Therefore, identity, purity, safety, and the quality of the
products are critical. A Deviation can define as "a
deviation from an approved instruction or established
standard" The deviation process helps identify potential
risks to product quality and patient safety and establish
the root cause. Once the root cause identifies,
appropriate corrective and preventive actions take to
prevent reoccurrence. OOS defines as "A result that is
outside the specifications or acceptance criteria
established by the manufacturer or laboratory" As the
industry moves to newer and more complicated
products, quality control procedures must be in place to
ensure consistent product quality. "CAPA defined by
corrections.
Keywords :
Deviation; Out-of-Specification (OOS); Corrective and Preventive Action (CAPA).